ONC-392 drug page Clinical trials

Trials with ONC-392

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

1Trials
0Recruiting
2Countries
733Planned patients

Showing 1–1 of 1

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Ongoing, not recruiting Phase 1 733 patients NCT04140526

This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants …

United States, Australia Sept 2020 – Dec 2027 Interventional
Combined with: DocetaxelPembrolizumab